Franklin Genomic Advancements ETF holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.
Franklin Genomic Advancements ETF HELX
Morningstar’s Analysis HELX
Will HELX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 48.1
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Guardant Health Inc | 9.31 | 3M | Healthcare |
Natera Inc | 8.59 | 3M | Healthcare |
Krystal Biotech Inc | 5.81 | 2M | Healthcare |
Ligand Pharmaceuticals Inc | 4.33 | 1M | Healthcare |
Adaptive Biotechnologies Corp | 4.30 | 1M | Healthcare |
Twist Bioscience Corp | 3.60 | 1M | Healthcare |
BridgeBio Pharma Inc | 3.35 | 1M | Healthcare |
Travere Therapeutics Inc Ordinary Shares | 3.15 | 989,188 | Healthcare |
Vertex Pharmaceuticals Inc | 2.88 | 903,829 | Healthcare |
Corteva Inc | 2.74 | 861,028 | Basic Materials |